ES2826826T3 - Combinación farmacéutica que comprende irinotecán liposómico, oxaliplatino, 5-fluorouracilo y leucovorina para el tratamiento del cáncer pancreático metastático - Google Patents
Combinación farmacéutica que comprende irinotecán liposómico, oxaliplatino, 5-fluorouracilo y leucovorina para el tratamiento del cáncer pancreático metastático Download PDFInfo
- Publication number
- ES2826826T3 ES2826826T3 ES16758337T ES16758337T ES2826826T3 ES 2826826 T3 ES2826826 T3 ES 2826826T3 ES 16758337 T ES16758337 T ES 16758337T ES 16758337 T ES16758337 T ES 16758337T ES 2826826 T3 ES2826826 T3 ES 2826826T3
- Authority
- ES
- Spain
- Prior art keywords
- oxaliplatin
- liposomal irinotecan
- leucovorin
- irinotecan
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title claims abstract description 384
- 229960004768 irinotecan Drugs 0.000 title claims abstract description 381
- 229960002949 fluorouracil Drugs 0.000 title claims abstract description 313
- 229960001756 oxaliplatin Drugs 0.000 title claims abstract description 313
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 title claims abstract description 313
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title claims abstract description 312
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 title claims abstract description 225
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 title claims abstract description 208
- 235000008191 folinic acid Nutrition 0.000 title claims abstract description 208
- 239000011672 folinic acid Substances 0.000 title claims abstract description 208
- 229960001691 leucovorin Drugs 0.000 title claims abstract description 208
- 206010061289 metastatic neoplasm Diseases 0.000 title claims abstract description 42
- 230000001394 metastastic effect Effects 0.000 title claims abstract description 39
- 238000011282 treatment Methods 0.000 title claims description 131
- 206010061902 Pancreatic neoplasm Diseases 0.000 title description 48
- 201000002528 pancreatic cancer Diseases 0.000 title description 48
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title description 47
- 208000008443 pancreatic carcinoma Diseases 0.000 title description 47
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 77
- 230000000118 anti-neoplastic effect Effects 0.000 claims abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 40
- 210000000496 pancreas Anatomy 0.000 claims abstract description 30
- 208000009956 adenocarcinoma Diseases 0.000 claims abstract description 29
- 238000002512 chemotherapy Methods 0.000 claims abstract description 15
- 238000001802 infusion Methods 0.000 claims description 42
- 239000002502 liposome Substances 0.000 claims description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 229920002505 N-(Carbonyl-Methoxypolyethylene Glycol 2000)-1,2-Distearoyl-Sn-Glycero-3-Phosphoethanolamine Polymers 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 claims description 6
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 5
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 claims description 5
- 229940071238 n-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine Drugs 0.000 claims 1
- PMZSPINGJVBHAT-DJBCQDJXSA-N irinotecan sucrosofate Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1.OS(=O)(=O)O[C@H]1[C@@H](OS(O)(=O)=O)[C@@H](COS(=O)(=O)O)O[C@@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 PMZSPINGJVBHAT-DJBCQDJXSA-N 0.000 description 211
- 206010028980 Neoplasm Diseases 0.000 description 64
- 230000002829 reductive effect Effects 0.000 description 46
- 231100000419 toxicity Toxicity 0.000 description 45
- 230000001988 toxicity Effects 0.000 description 45
- 238000009097 single-agent therapy Methods 0.000 description 29
- 230000009467 reduction Effects 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 25
- 229940079593 drug Drugs 0.000 description 25
- 239000003814 drug Substances 0.000 description 25
- 230000004048 modification Effects 0.000 description 25
- 238000012986 modification Methods 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 230000004044 response Effects 0.000 description 22
- 238000001990 intravenous administration Methods 0.000 description 21
- 231100000226 haematotoxicity Toxicity 0.000 description 20
- PJZDLZXMGBOJRF-CXOZILEQSA-L folfirinox Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 17
- 229960005277 gemcitabine Drugs 0.000 description 17
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 17
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 16
- 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 description 16
- 101710205316 UDP-glucuronosyltransferase 1A1 Proteins 0.000 description 16
- 230000002411 adverse Effects 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 229960001592 paclitaxel Drugs 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 16
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 16
- 230000004614 tumor growth Effects 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 229950010538 irinotecan hydrochloride trihydrate Drugs 0.000 description 15
- 238000002648 combination therapy Methods 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 13
- 208000004235 neutropenia Diseases 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 12
- 230000002035 prolonged effect Effects 0.000 description 12
- 206010012735 Diarrhoea Diseases 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- KLEAIHJJLUAXIQ-JDRGBKBRSA-N irinotecan hydrochloride hydrate Chemical compound O.O.O.Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 KLEAIHJJLUAXIQ-JDRGBKBRSA-N 0.000 description 10
- 229940048191 onivyde Drugs 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 238000011284 combination treatment Methods 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 108700028369 Alleles Proteins 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 230000003111 delayed effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940090044 injection Drugs 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000003442 weekly effect Effects 0.000 description 7
- 206010061818 Disease progression Diseases 0.000 description 6
- 108010022394 Threonine synthase Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000005750 disease progression Effects 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 6
- 230000002489 hematologic effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 229940034982 antineoplastic agent Drugs 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 229960003957 dexamethasone Drugs 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 5
- 206010043554 thrombocytopenia Diseases 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 208000002633 Febrile Neutropenia Diseases 0.000 description 4
- 206010061188 Haematotoxicity Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000003474 anti-emetic effect Effects 0.000 description 4
- 239000002111 antiemetic agent Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000017095 negative regulation of cell growth Effects 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000009101 premedication Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 102000005497 Thymidylate Synthase Human genes 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 102000004419 dihydrofolate reductase Human genes 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940014144 folate Drugs 0.000 description 3
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- -1 for example Chemical compound 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 3
- CUGZEDSDRBMZMY-UHFFFAOYSA-N trihydrate;hydrochloride Chemical compound O.O.O.Cl CUGZEDSDRBMZMY-UHFFFAOYSA-N 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000037844 advanced solid tumor Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 238000009096 combination chemotherapy Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002650 habitual effect Effects 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 2
- 230000005195 poor health Effects 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 230000000970 DNA cross-linking effect Effects 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101500028021 Drosophila melanogaster Immune-induced peptide 16 Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000002375 Hand-Foot Syndrome Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 240000007019 Oxalis corniculata Species 0.000 description 1
- 235000016499 Oxalis corniculata Nutrition 0.000 description 1
- 206010033553 Palmar-plantar erythrodysaesthesia syndrome Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 229940086245 acetaminophen 650 mg Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- JSRLJPSBLDHEIO-SHYZEUOFSA-N dUMP Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 JSRLJPSBLDHEIO-SHYZEUOFSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940041216 diphenhydramine hydrochloride 50 mg Drugs 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 229940039472 irinotecan injection Drugs 0.000 description 1
- 229940048115 irinotecan liposomal Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940008678 levoleucovorin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 230000006824 pyrimidine synthesis Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000013413 tumor xenograft mouse model Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562208209P | 2015-08-21 | 2015-08-21 | |
| US201562216736P | 2015-09-10 | 2015-09-10 | |
| US201562273244P | 2015-12-30 | 2015-12-30 | |
| US201662281473P | 2016-01-21 | 2016-01-21 | |
| US201662302341P | 2016-03-02 | 2016-03-02 | |
| US201662323245P | 2016-04-15 | 2016-04-15 | |
| US201662343313P | 2016-05-31 | 2016-05-31 | |
| PCT/US2016/047727 WO2017034957A1 (en) | 2015-08-21 | 2016-08-19 | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2826826T3 true ES2826826T3 (es) | 2021-05-19 |
Family
ID=58100730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16758337T Active ES2826826T3 (es) | 2015-08-21 | 2016-08-19 | Combinación farmacéutica que comprende irinotecán liposómico, oxaliplatino, 5-fluorouracilo y leucovorina para el tratamiento del cáncer pancreático metastático |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US20170049775A1 (OSRAM) |
| EP (2) | EP3791876A1 (OSRAM) |
| JP (3) | JP2018528185A (OSRAM) |
| KR (1) | KR102714060B1 (OSRAM) |
| CN (1) | CN108495629A (OSRAM) |
| AU (1) | AU2016310476B8 (OSRAM) |
| BR (1) | BR112018002941B1 (OSRAM) |
| ES (1) | ES2826826T3 (OSRAM) |
| HK (1) | HK1257220A1 (OSRAM) |
| IL (1) | IL257149B2 (OSRAM) |
| MX (1) | MX385425B (OSRAM) |
| PT (1) | PT3337478T (OSRAM) |
| RU (1) | RU2747124C2 (OSRAM) |
| SG (1) | SG10201913077QA (OSRAM) |
| SI (1) | SI3337478T1 (OSRAM) |
| TW (5) | TW202126293A (OSRAM) |
| WO (1) | WO2017034957A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| EP3229802A1 (en) * | 2014-12-09 | 2017-10-18 | Ipsen Biopharm Ltd. | Treatment of breast cancer with liposomal irinotecan |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| SG10201913073YA (en) | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| SG10201913077QA (en) * | 2015-08-21 | 2020-02-27 | Ipsen Biopharm Ltd | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
| CN114073678A (zh) | 2015-10-16 | 2022-02-22 | 易普森生物制药有限公司 | 稳定喜树碱药物组合物 |
| BR112019007844A2 (pt) | 2016-11-02 | 2019-07-16 | Ipsen Biopharm Ltd | tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina) |
| AU2019360044B2 (en) * | 2018-10-17 | 2025-01-30 | Biolinerx Ltd. | Treatment of metastatic pancreatic adenocarcinoma |
| EP3911353A1 (en) * | 2019-01-17 | 2021-11-24 | BioLineRx Ltd. | Specific combination therapy for treatment of pancreatic cancer |
| WO2020148744A1 (en) * | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Combination therapy for treatment of pancreatic cancer |
| EP3988085A1 (en) * | 2019-02-22 | 2022-04-27 | Novocure GmbH | Treating gastric cancer using ttfields and drug in combination |
| US20220378936A1 (en) * | 2019-10-10 | 2022-12-01 | The University Of North Carolina At Chapel Hill | Delivery system complexes comprising a precipitate of an active agent and methods of use |
| WO2022266357A1 (en) * | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and napox |
| EP4355366A4 (en) * | 2021-06-16 | 2025-05-07 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and napoli |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
| IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5538954A (en) | 1994-06-24 | 1996-07-23 | A/S Dumex (Dumex Ltd.) | Salts of tetracyclines |
| US5783568A (en) | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| DE19605024A1 (de) | 1996-01-31 | 1997-08-07 | Schering Ag | Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
| WO1998017256A1 (en) | 1996-10-22 | 1998-04-30 | Dmitri Kirpotin | Compound-loaded liposomes and methods for their preparation |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
| US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| US6726925B1 (en) | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
| US6355268B1 (en) | 1998-09-16 | 2002-03-12 | Alza Corporation | Liposome-entrapped topoisomerase inhibitors |
| US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| WO2001056548A2 (en) | 2000-02-04 | 2001-08-09 | Lipoxen Technologies Limited | Liposomes composition produced by a dehydration-rehydration process |
| US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
| DK1286671T3 (da) | 2000-05-15 | 2006-07-17 | Celgene Corp | Sammensætninger til behandling af colorektal cancer hvilke indeholder thalidomid og irinotecan |
| CN1245977C (zh) | 2000-06-30 | 2006-03-22 | 英耐克斯药品股份有限公司 | 脂质体抗肿瘤药物及其使用 |
| TWI283575B (en) | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
| NZ528523A (en) | 2001-03-26 | 2006-03-31 | Alza Corp | Liposome composition for improved intracellular delivery of a therapeutic agent |
| US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
| WO2003030864A1 (en) | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
| EP1408973A2 (en) | 2001-07-23 | 2004-04-21 | Epidauros Biotechnologie AG | Means and methods for improved treatment of cancer based on mrp1 |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| CA2486007C (en) | 2002-05-15 | 2011-11-22 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
| EP2431385A3 (en) | 2002-05-31 | 2012-07-04 | Morphotek, Inc. | Combination therapy with chlorotoxin |
| AU2003296897A1 (en) | 2002-08-20 | 2004-05-04 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
| MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
| CN103948545B (zh) | 2004-05-03 | 2017-10-03 | 益普生生物制药公司 | 用于药物输送的脂质体 |
| US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| MXPA06013874A (es) | 2004-06-01 | 2007-04-25 | Terumo Corp | Formulacion de irinotecan. |
| JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| US7842676B2 (en) | 2005-10-25 | 2010-11-30 | Celator Pharmaceuticals, Inc. | Fixed ratio drug combination treatments for solid tumors |
| EP1976485A4 (en) | 2005-12-22 | 2011-10-26 | Celator Pharmaceuticals Inc | LIPOSOMAL FORMULATIONS WITH SECONDARY AND TERTIARY AMINES AND METHOD OF MANUFACTURING THEREOF |
| DK2338487T3 (da) | 2006-01-17 | 2013-12-09 | Abbvie Bahamas Ltd | Kombinationsterapi med PARP-inhibitorer |
| EP2004175A4 (en) | 2006-03-16 | 2010-12-15 | Bionumerik Pharmaceuticals Inc | COMPOUNDS AND FORMULATIONS FOR INCREASING THE EFFECT OF CANCER AND METHOD FOR THEIR USE |
| BRPI0808055A2 (pt) | 2007-02-16 | 2013-07-30 | Merrimack Pharmaceuticals Inc | anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, composiÇço, Ácido nucleico isolado, vetor de expressço, cÉlula hospedeira, hibridoma, kit, uso de um anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, mÉtodo para diagnosticar um cÂncer associado com erbb3 em um paciente, e, anticorpo |
| US20120003160A1 (en) | 2007-06-29 | 2012-01-05 | Amag Pharmaceuticals, Inc. | Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session |
| EP2187869B1 (en) | 2007-08-17 | 2015-10-14 | Celator Pharmaceuticals, Inc. | Improved platinum drug formulations |
| CA2700810A1 (en) | 2007-09-28 | 2009-04-02 | Universitatsspital Basel | Immunoliposomes for treatment of cancer |
| SG185954A1 (en) | 2007-11-12 | 2012-12-28 | Bipar Sciences Inc | Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
| US20090149397A1 (en) | 2007-12-07 | 2009-06-11 | Bipar Sciences | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| US20110104256A1 (en) | 2008-03-25 | 2011-05-05 | Yaolin Wang | Methods for treating or preventing colorectal cancer |
| US8067432B2 (en) | 2008-03-31 | 2011-11-29 | University Of Kentucky Research Foundation | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors |
| EA022201B1 (ru) | 2008-04-11 | 2015-11-30 | Мерримак Фармасьютикалз, Инк. | Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение |
| US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
| US20100022444A1 (en) * | 2008-07-24 | 2010-01-28 | Bodybio, Inc. | Combination therapy for modulation of activity and development of cells and tissues |
| US8927694B2 (en) | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| RU2011142806A (ru) | 2009-05-01 | 2013-06-10 | ОНКОЗИМ ФАРМА ИНК. (Канада) | Комбинации пентамидина для лечения рака |
| CA2782911C (en) | 2009-12-03 | 2016-08-23 | Jiangsu Hengrui Medicine Co., Ltd. | Liposome of irinotecan or its hydrochloride and preparation method thereof |
| RU2576609C2 (ru) | 2010-06-04 | 2016-03-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечение рака поджелудочной железы |
| MX2013000779A (es) | 2010-07-19 | 2013-07-05 | Bipar Sciences Inc | Metodos para tratar cancer de mama utilizando 4-yodo-3-nitrobenzamida en combinacion con agentes antitumorales. |
| RU2598711C2 (ru) | 2010-07-22 | 2016-09-27 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Антитело к противоопухолевому антигену и способы применения |
| WO2012031293A1 (en) | 2010-09-03 | 2012-03-08 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the treatment of cancer |
| CN107252417A (zh) | 2010-12-06 | 2017-10-17 | 梅里麦克制药股份有限公司 | 在使用包含蒽环类化疗剂的erbb2靶向免疫脂质体的治疗中防止心肌毒性的剂量和给药 |
| EP2651447B1 (en) | 2010-12-14 | 2018-08-29 | Technical University of Denmark | Entrapment of radionuclides in nanoparticle compositions |
| CA2827118A1 (en) | 2011-02-15 | 2012-08-23 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
| CA2833643A1 (en) | 2011-04-19 | 2012-10-26 | Merrimack Pharmaceuticals, Inc. | Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| WO2013138371A1 (en) | 2012-03-12 | 2013-09-19 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody |
| JP6245481B2 (ja) | 2012-04-17 | 2017-12-13 | メリマック ファーマシューティカルズ インコーポレーティッド | 非侵襲的イメージングのための組成物および方法 |
| AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013374248A1 (en) | 2012-12-14 | 2015-06-11 | Merrimack Pharmaceuticals, Inc. | Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents |
| TWI641374B (zh) | 2013-03-27 | 2018-11-21 | 大鵬藥品工業股份有限公司 | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 |
| EP3038600B1 (en) | 2013-08-27 | 2020-06-03 | Northeastern University | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
| US20160303264A1 (en) | 2013-10-23 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for non-invasive imaging and drug delivery |
| EP3229802A1 (en) | 2014-12-09 | 2017-10-18 | Ipsen Biopharm Ltd. | Treatment of breast cancer with liposomal irinotecan |
| TW201701880A (zh) | 2015-04-14 | 2017-01-16 | 莫瑞麥克製藥公司 | 改善持續釋放藥物治療之藥物動力學及治療指數之方法 |
| SG10201913073YA (en) | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| SG10201913077QA (en) | 2015-08-21 | 2020-02-27 | Ipsen Biopharm Ltd | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
| CN114073678A (zh) | 2015-10-16 | 2022-02-22 | 易普森生物制药有限公司 | 稳定喜树碱药物组合物 |
| US20170202840A1 (en) | 2016-01-14 | 2017-07-20 | Merrimack Pharmaceuticals, Inc. | Treatment of pancreatic cancer with liposomal irinotecan |
| WO2017172678A1 (en) | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| MX394766B (es) | 2016-05-18 | 2025-03-24 | Ipsen Biopharm Ltd | Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas. |
| US20170333421A1 (en) | 2016-05-18 | 2017-11-23 | Ipsen Biopharm Ltd. | Population Pharmacokinetics of Liposomal Irinotecan |
| CN106420789A (zh) * | 2016-10-08 | 2017-02-22 | 中国人民解放军总医院 | 复发耐药消化道肿瘤地西他滨综合治疗方案 |
| BR112019007844A2 (pt) | 2016-11-02 | 2019-07-16 | Ipsen Biopharm Ltd | tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina) |
-
2016
- 2016-08-19 SG SG10201913077QA patent/SG10201913077QA/en unknown
- 2016-08-19 TW TW109134982A patent/TW202126293A/zh unknown
- 2016-08-19 EP EP20190127.9A patent/EP3791876A1/en active Pending
- 2016-08-19 RU RU2018105666A patent/RU2747124C2/ru active
- 2016-08-19 SI SI201630927T patent/SI3337478T1/sl unknown
- 2016-08-19 JP JP2018506600A patent/JP2018528185A/ja not_active Withdrawn
- 2016-08-19 WO PCT/US2016/047727 patent/WO2017034957A1/en not_active Ceased
- 2016-08-19 IL IL257149A patent/IL257149B2/en unknown
- 2016-08-19 US US15/241,106 patent/US20170049775A1/en not_active Abandoned
- 2016-08-19 TW TW105126833A patent/TWI778942B/zh active
- 2016-08-19 TW TW113117993A patent/TW202508602A/zh unknown
- 2016-08-19 ES ES16758337T patent/ES2826826T3/es active Active
- 2016-08-19 TW TW111103869A patent/TW202243677A/zh unknown
- 2016-08-19 HK HK18116225.3A patent/HK1257220A1/zh unknown
- 2016-08-19 CN CN201680046873.3A patent/CN108495629A/zh active Pending
- 2016-08-19 BR BR112018002941-6A patent/BR112018002941B1/pt active IP Right Grant
- 2016-08-19 PT PT167583376T patent/PT3337478T/pt unknown
- 2016-08-19 AU AU2016310476A patent/AU2016310476B8/en active Active
- 2016-08-19 EP EP16758337.6A patent/EP3337478B1/en active Active
- 2016-08-19 TW TW112110238A patent/TW202400181A/zh unknown
- 2016-08-19 MX MX2018001802A patent/MX385425B/es unknown
- 2016-08-19 KR KR1020187005220A patent/KR102714060B1/ko active Active
-
2017
- 2017-11-10 US US15/809,815 patent/US11344552B2/en active Active
-
2021
- 2021-10-28 JP JP2021176412A patent/JP7463329B2/ja active Active
-
2022
- 2022-04-01 US US17/711,500 patent/US20230062425A1/en not_active Abandoned
-
2024
- 2024-02-16 JP JP2024022222A patent/JP2024045587A/ja active Pending
- 2024-05-29 US US18/676,591 patent/US20240358706A1/en not_active Abandoned
-
2025
- 2025-04-24 US US19/188,672 patent/US20250381191A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2826826T3 (es) | Combinación farmacéutica que comprende irinotecán liposómico, oxaliplatino, 5-fluorouracilo y leucovorina para el tratamiento del cáncer pancreático metastático | |
| TWI791467B (zh) | 使用包含微脂體伊立替康（ｉｒｉｎｏｔｅｃａｎ）、奧沙利鉑（ｏｘａｌｉｐｌａｔｉｎ）、５-氟尿嘧啶及甲醯四氫葉酸（ｌｅｕｃｏｖｏｒｉｎ）之組合療法治療胃癌 | |
| ES2848118T3 (es) | Terapia de combinación que usa irinotecán liposomal y un inhibidor de PARP para el tratamiento del cáncer | |
| ES2550759T3 (es) | Formulaciones farmacológicas de platino mejoradas | |
| Waizenegger et al. | Trial in progress: phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation | |
| ES2389809T3 (es) | Terapias anticancerosas | |
| CA2993451C (en) | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin | |
| ES3017257T3 (en) | Abt-751 and ionizing radiation for use in treating a brain tumor | |
| HK40045473A (en) | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin | |
| HK1257250B (en) | Drug combination comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin for treating metastatic pancreatic cancer | |
| HK40009222A (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |